Answers are grounded in this paper and cite their sources.
Clinical evaluation reports cardiovascular risk related to elevated lipoprotein(a) in primary and secondary prevention cohorts, highlighting conflicting roles of inflammation.
Elevated lipoprotein(a) (Lp[a]) is a putative causal risk factor for atherosclerotic cardiovascular disease (ASCVD). There are conflicting data as to whether Lp(a) may increase cardiovascular risk only in the presence of concomitant inflammation.
No takes yet. Share an insight, caveat, or question.
Small et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: